Trial Profile

Phase 1/2, Open-label, Multicenter, First-in-Human Study of DS-3939a in Subjects With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 25 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DS 3939 (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Biliary cancer; Male breast cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Urogenital cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Daiichi Sankyo Inc

Most Recent Events

30 Jan 2025 Planned number of patients changed from 430 to 470.
04 Jun 2024 Study design presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
10 Apr 2024 Trial design presented at the 115th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com